Femoral Arteriotomy Closure

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Essential PharmaceuticalsNC - Raleigh

6 programs

CE-marked MANTA vascular closure deviceN/A1 trial

MANTA Vascular Closure DeviceN/A1 trial

MANTA vascular closure deviceN/A1 trial

+1 more programs

Active Trials

NCT03330002Completed500Est. Feb 2021

NCT02521948Completed50Est. May 2016

NCT05142566Terminated17Est. Jan 2023

+3 more trials

Teleflex MedicalAustralia - Mascot

2 programs

MANTA Vascular Closure DeviceN/A

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Essential PharmaceuticalsMANTA Vascular Closure Device

Essential PharmaceuticalsCE-marked MANTA vascular closure device

Essential PharmaceuticalsMANTA vascular closure device

Essential PharmaceuticalsMANTA Vascular Closure Device

Essential PharmaceuticalsX-Seal 6F Vascular Closure Device

Clinical Trials (6)

Total enrollment: 1,135 patients across 6 trials

NCT05936996 Essential PharmaceuticalsMANTA Vascular Closure Device

Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

Start: Nov 2023Est. completion: Oct 2025258 patients

N/ACompleted

NCT05142566 Essential PharmaceuticalsMANTA Vascular Closure Device

MANTA Ultrasound Closure Study

Start: Aug 2022Est. completion: Jan 202317 patients

N/ATerminated

NCT03330002 Essential PharmaceuticalsCE-marked MANTA vascular closure device

MANTA Registry for Vascular Large-bore Closure

Start: Feb 2018Est. completion: Feb 2021500 patients

N/ACompleted

NCT02908880 Essential PharmaceuticalsMANTA vascular closure device

MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study

Start: Dec 2016Est. completion: Dec 2017263 patients

N/ACompleted

NCT02521948 Essential PharmaceuticalsMANTA Vascular Closure Device

Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device

Start: Jul 2015Est. completion: May 201650 patients

N/ACompleted

NCT02406612 Essential PharmaceuticalsX-Seal 6F Vascular Closure Device

X-Seal EU Post-Market Clinical Follow-Up Protocol

Start: Apr 2015Est. completion: Jun 201647 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.